Taxane
- Generic Name
- Taxane
A Study of BL-M07D1 + Pertuzumab With or Without Taxane Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
- Conditions
- HER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06891833
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
🇨🇳Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui, China
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
- Conditions
- HER2-negative Breast CancerAdvanced Breast Cancer
- Interventions
- Drug: Organoid-guided treatmentDrug: Anthracycline
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 252
- Registration Number
- NCT06102824
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients
- Conditions
- TrastuzumabHER2-positive Gastric CancerMetastatic CancerDocetaxel
- Interventions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 65
- Registration Number
- NCT04920747
- Locations
- 🇫🇷
CHU Besancon, Besançon, Franche-Comté, France
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
- Conditions
- Breast Cancer; HER2-positive; Metastatic
- Interventions
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1157
- Registration Number
- NCT04784715
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients
- Conditions
- Early Breast Cancer
- Interventions
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 200
- Registration Number
- NCT04293393
- Locations
- 🇪🇸
Hospital Universitario de Burgos, Burgos, Spain
🇪🇸Hospital Universitario Ramón y Cajal, Madrid, Spain
🇪🇸Hospital General Universitario de Alicante, Alicante, Spain
Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy
- Conditions
- Breast CancerBreast Neoplasms
- Interventions
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 5
- Registration Number
- NCT03393741
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
- Conditions
- Triple-Negative Breast NeoplasmER-Negative PR-Negative HER2-Negative Breast NeoplasmsER-Negative PR-Negative HER2-Negative Breast CancerBreast CancerTriple Negative Breast NeoplasmsTriple-Negative Breast CancerTriple Negative Breast Cancer
- Interventions
- Biological: Bavituximab
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Peregrine Pharmaceuticals
- Registration Number
- NCT02685306
Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Peregrine Pharmaceuticals
- Registration Number
- NCT02651610
- Locations
- 🇺🇸
Peregrine Pharmaceuticals Investigational Site, Tinley Park, Illinois, United States
Prospective Study of Fertility-sparing Treatment Strategy in Patients With Early Cervical Cancer(SYSUGO-005/CSEM009)
- Conditions
- Cervical Cancer
- Interventions
- Procedure: radical trachelectomy
- First Posted Date
- 2015-12-08
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 60
- Registration Number
- NCT02624531
- Locations
- 🇨🇳
Clinical Trial Center, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
- Conditions
- Carcinoma, Non-Small-Cell LungNeuroendocrine TumorsSmall Cell CarcinomaOvarian Epithelial Cancer
- Interventions
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 139
- Registration Number
- NCT02489903
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Baptist Health, Lexington, Kentucky, United States
🇺🇸Memorial Hospital of South Bend, South Bend, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.